{"id":"W4410877876","doi":"10.1016/s2468-1253(25)00071-8","title":"Safety and efficacy of the anti-TL1A monoclonal antibody tulisokibart for Crohn's disease: a phase 2a induction trial","year":2025,"lang":"en","type":"article","venue":"˜The œLancet. Gastroenterology & hepatology","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":25,"is_retracted":false,"has_abstract":false,"ca_institutions":"Western University","funders":"Prometheus Biosciences; Prometheus","keywords":"Crohn's disease; Monoclonal antibody; Medicine; Disease; Immunology; Monoclonal; Clinical trial; Antibody; Internal medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001798581,0.001146186,0.00173951,0.0002796279,0.0003488639,0.001182471,0.0007524886,0.001540005,0.003554049],"category_scores_gemma":[0.001045489,0.0003585988,0.001341954,0.0003044696,0.0008155676,0.0008652502,0.000283787,0.003322553,0.0008972731],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000946157,"about_ca_system_score_gemma":0.0008472165,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004945304,"about_ca_topic_score_gemma":0.00094838,"domain_scores_codex":[0.9995553,0.0002086676,0.00002131576,0.00005638633,0.00004319309,0.0001152198],"domain_scores_gemma":[0.9992666,0.0002221556,0.0001728416,0.000058899,0.00004306616,0.000236393],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8565026,0.01130749,0.002449736,0.001023175,0.001547122,0.0001562629,0.00009698024,0.001063916,0.01391338,0.0003196714,0.003731893,0.1078877],"study_design_scores_gemma":[0.7958297,0.1873458,0.009462741,0.0001227771,0.0009473373,0.0001986223,0.00004952174,0.0008233459,0.001984588,0.0003554918,0.002845447,0.00003460995],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9808235,0.01245302,0.0004802461,0.001412775,0.0003362123,0.0006522983,0.0008827057,0.00009379839,0.002865392],"genre_scores_gemma":[0.9874462,0.004848511,0.0005724693,0.001609503,0.0003732661,0.0009177009,0.001330779,0.00002633524,0.002875246],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003554049,"threshold_uncertainty_score":0.01188946,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01159665946143813,"score_gpt":0.2937988253067598,"score_spread":0.2822021658453217,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}